QURE
uniQure N.V.
NASDAQ · NLHealthcareBiotechnology
$39.70-1.37%
Price as of Jul 20, 2026
QURE financials
uniQure N.V. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $16.1M | $27.1M | $15.8M | $106.5M |
| Cost of revenue | $1.7M | $18.3M | $13.6M | $3.3M |
| Gross profit | $14.4M | $8.8M | $2.2M | $103.1M |
| Operating expenses | $202.2M | $193.1M | $285.1M | $246.3M |
| Operating income | -$187.8M | -$184.3M | -$282.9M | -$143.2M |
| Net income | -$199.0M | -$239.6M | -$308.5M | -$126.8M |
| EBITDA | -$116.6M | -$160.7M | -$253.1M | -$108.0M |
| Basic EPS | $-3.46 | $-4.92 | $-6.47 | $-2.71 |
| Diluted EPS | $-3.46 | $-4.92 | $-6.47 | $-2.71 |
| Balance sheet | ||||
| Cash & equivalents | $80.2M | $158.9M | $241.4M | $228.0M |
| Total assets | $824.9M | $556.5M | $831.7M | $705.0M |
| Total liabilities | $626.0M | $563.3M | $624.0M | $229.0M |
| Stockholders’ equity | $198.9M | -$6.8M | $207.7M | $476.0M |
| Total debt | $536.6M | $66.1M | $138.4M | $142.9M |
| Net debt | $456.4M | -$92.9M | -$103.0M | -$85.1M |
| Cash flow | ||||
| Operating cash flow | -$178.0M | -$182.7M | -$145.9M | -$145.1M |
| Capital expenditure | -$439.0K | -$3.4M | -$7.2M | -$17.7M |
| Free cash flow | -$178.0M | -$186.1M | -$153.1M | -$162.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |